HIV-associated Co-morbidities: The Lingering Challenge

People living with HIV have an enhanced risk of developing various other conditions, even when HIV is treated with antiretroviral therapy. Hence, HIV-associated comorbidities must be addressed to improve the health of people already with HIV, reports a new study. The findings of the study are published in the journal JAMA. Previous commentaries detailed the proposed Ending the HIV Epidemic: A Plan for America, which aims to reduce new HIV transmissions in the United States by 75% in five years and 90% in 10 years, and discussed the challenges posed by the emerging opioid injection epidemic in rural areas.

Assuming the aspirational goals of Ending the HIV Epidemic are achieved, at least one million people in the United States still will be living with the virus. With effective antiretroviral therapy (ART), people with HIV can expect a near-normal lifespan. But even when treated with ART, people living with HIV are at heightened risk for numerous comorbidities, including heart disease, kidney disease, osteoporosis, liver disease, certain cancers and neurocognitive disease.

Successfully addressing HIV-associated comorbidities will require research advances to understand better how these conditions develop, write Anthony S. Fauci, MD, director of NIH's National Institute of Allergy and Infectious Diseases (NIAID), and colleagues. Clinical trials to assess treatments for HIV-associated comorbidities and efforts to reduce health care disparities also must be prioritized.

Insight into the mechanisms underlying the chronic immune activation and dysfunction associated with HIV could lead to new therapies to manage numerous HIV-associated comorbidities, including heart disease. In this regard, the REPRIEVE clinical trial is investigating whether a statin medication can reduce the risk of cardiovascular disease among people with HIV. Other factors involved in driving HIV-associated comorbidities include side effects of long-term ART use, such as lowered bone mineral density, and coinfections, such as viral hepatitis.

Source-Eurekalert